Oppenheimer Reiterates Outperform Rating on UroGen Pharma (URGN), 'top pick and regard current levels as attractive ahead of upcoming newsflow'
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $40.00 price target on UroGen Pharma (NASDAQ: URGN)The analyst comments "Last ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
